Healthcare

Surgical Science Sweden AB (publ)(SUSRF)

Live Price

Offline

$4.00

+0.00% today

1Y Change

-73.51%

Window

Jun 20, 2025 → Jun 19, 2026

Market Cap: $1.67B
Revenue Growth: +12.0%
EPS Growth: -50.0%
Dividend Yield: 0.0%

Coverage: 256 bars · Jun 20, 2025 → Jun 19, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Surgical Science Sweden AB (publ) (SUSRF) is a Healthcare stock with a market cap of $1.67B and listed on OTC. The stock last traded around $4.00 and down 73.5% across the available one-year price window (Jun 20, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of +12.0%, EPS growth of -50.0%, a dividend yield of 0.0%. What stands out right now is revenue +12.0%, EPS -50.0%, free cash flow -24.2% with operating margin 7.6% and ROIC 1.1%. Valuation is more restrained than many high-expectation growth names at P/E 25.1 and price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SUSRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+12.0% vs +7.6% peer median

Operating Margin

Below sector median

+7.6% vs +19.4% peer median

P/E

Below sector median

25.1 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 20, 2026, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at +12.0% and EPS is at -50.0%, with operating margin around 7.6%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged -0.7% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table

Quarter	EPS Δ	1D	5D	20D
2026 May 20, 2026	—	+0.0%	-2.2%	-2.2%
2026 Feb 19, 2026	-3.5%	+0.0%	+0.0%	+0.0%
2025 Nov 13, 2025	-43.3%	+0.0%	+0.0%	-57.7%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SUSRF

—

Normalized return

SPY

—

S&P 500

Excess Return

—

Relative to SPY

SUSRF Max Drawdown

-81.64%

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SUSRF and SPY.

Calendar-year return history is still loading or unavailable.

Company Overview

Surgical Science Sweden AB (publ)

Other OTC

Gothenburg, SE

Visit surgicalscience.com Call IR46 3 17 41 65 60

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.

Leadership: Tom Englund
IPO Date: Jan 21, 2021
Employees: 274

Street Address: Drakegatan 7 A, 3 tr.
Mailing: Gothenburg, 412 50
Region: Gothenburg, SE

Reporting Currency: USD
Investor Line: 46 3 17 41 65 60
Last Updated: May 5, 2026

ISIN: SE0014428512

Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E: 25.1
EV/EBITDA: 8.1
Price/Sales: 1.7
Price/Book: 0.4

Growth

Revenue: +12.0%
EPS: -50.0%
Free Cash Flow: -24.2%

Profitability

Gross Margin: 63.9%
Operating Margin: 7.6%
Net Margin: 6.7%
ROE: 1.5%
ROIC: 1.1%

Balance Sheet

Debt/Equity: 0.00
Current Ratio: 4.07

Earnings Reports

📅 Last reportedMay 20, 2026

Period	B/M	EPS	EPS Δ	Revenue	Rev Δ
— May 20, 26		— Est 0.04	—	— Est 24851.8B	—
— Feb 19, 26	✗	0.07 Est 0.07	-3.5%	29105.8B Est 29024.7B	+0.3%
— Nov 13, 25	✗	0.04 Est 0.08	-43.3%	28114.7B Est 28329.8B	-0.8%
— Aug 21, 25	✗	-0.04 Est 0.08	-152.8%	21854.8B Est 30105.4B	-27.4%
— May 14, 25	✓	0.07 Est 0.04	+49.3%	25041.8B Est 26751.9B	-6.4%
— Feb 19, 25	✗	0.06 Est 0.09	-28.4%	22639.4B Est 24658.7B	-8.2%
— Nov 14, 24	✓	0.08 Est 0.07	+13.0%	22344.2B Est 24212.3B	-7.7%
— Aug 22, 24	✗	0.05 Est 0.07	-21.4%	20101.5B Est 20543.6B	-2.1%
— May 15, 24	✗	0.04 Est 0.08	-47.6%	17356.0B Est 20933.3B	-17.1%
— Mar 6, 24	✓	0.19 Est 0.12	+60.1%	22482.2B Est 26481.2B	-15.1%
— Sep 30, 23	✓	0.08 Est 0.06	+31.9%	19085.6B Est 20278.2B	-5.9%
— Jun 30, 23	✓	0.07 Est 0.07	+0.0%	19929.4B Est 20987.4B	-5.0%
— Mar 31, 23	✓	0.09 Est 0.05	+87.4%	22009.9B Est 18330.0B	+20.1%
— Feb 22, 23	✓	2.29 Est 0.82	+179.3%	24422.0B Est 22115.4B	+10.4%
— Nov 10, 22	✗	0.56 Est 0.63	-11.1%	18302.9B Est 17386.8B	+5.3%
— Aug 25, 22	✓	0.52 Est 0.50	+4.0%	18295.4B Est 16048.3B	+14.0%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official

No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guide Read how to compare stocks